Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04268706 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
A Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 5
- Study locations
NCT04268706 is a Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 97 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT04268706, a Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Bendamustine
- DRUG CD30.CAR-T
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
Illinois
- University of Chicago Medical Center - Chicago
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2037-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04268706
The ClinicalTrials.gov registry entry for NCT04268706 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tessa Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hodgkin Disease Recurrent appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT04268706 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04268706 about?
NCT04268706 is a clinical study titled "Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)". This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
What is the current status of trial NCT04268706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2021-02-01. Estimated completion is 2037-03.
What conditions does trial NCT04268706 study?
This clinical trial studies the following conditions: Hodgkin Disease Recurrent, Hodgkin Lymphoma, Adult, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric.
What interventions are being tested in trial NCT04268706?
The interventions under investigation include: Fludarabine (DRUG), Bendamustine (DRUG), CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT04268706?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04268706 being conducted?
This trial has 5 study locations across California, Illinois, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Disease Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.